Clear to Clinic - Streamline clinical development with Ypsomed

Ypsomed’s CliniPilot is an innovative add-on technology available in two versions, for YpsoMate 1 mL and 2.25 mL autoinjectors, transforming them into smart, connected devices, enabling connected clinical trials. It automatically captures and securely transmits key injection data—including time, date,...

Ypsomed provides pharmaceutical companies with fully integrated digital solutions. Our platform combines connected injection devices with comprehensive digital patient tools. Our aim is to facilitate research and development, shorten market access timelines and improve commercial success of subcutaneo...

Ypsomed’s platform portfolio offers advanced self-injection devices, including reusable and prefilled pens, autoinjectors, wearable injectors, and digital health solutions. Each platform is engineered in Switzerland for fast, efficient customisation, significantly reducing time to market and minimising dev...

YpsoMate 5.5 autoinjector is an automated injection device for 5.5mL pre-filled glass syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients.
• Taking handheld self-injection beyond volumes of 2.0 m...

YpsoDose is the pre-filled, ready-to-use patch injector designed for subcutaneous delivery of volumes up to 10 mL. With a powerful drive system capable of delivering 10 mL of 50 cp in 10 minutes, and an optimized fluid path that ensures minimal residual volume, YpsoDose supports a broad...

We proudly launch our proven YpsoMate® platform products equipped with the BD Neopak™ XtraFlow™ PFS with 8 mm needle and thin wall cannula. This new cutting-edge solution meets high-dose drug formulation demands by efficiently handling high viscosities and volumes. It highlights the strength of our Yps...

Uniting sustainability and patient convenience: YpsoLoop is a paradigm-shifting circular solution. It provides the convenience of a pre-filled, two-step, single-use device, while enabling material recovery through a design made for automated disassembly and efficient recycling. All of this is backed b...

Ypsomed’s autoinjector systems are automated disposable injection devices for 1ml and 2.25ml filled glass or polymer syringes suitable for all patient groups. The Ypsomed autoinjector family is typically used for the growing range of infrequently injected antibody-based drugs.Ypsomed’s autoinjector platfor...

 A pen injector is designed to support safe and effective self-injection, especially for people who require frequent dosing. It uses a pre-filled cartridge—usually 1.5 mL or 3 mL—typically containing a preserved drug solution that remains stable throughout the therapy duration. Pen injectors are avail...

YpsoFlow: The spring-driven pre-filled pen

Offering trusted usability and a smooth path to market.

YpsoFlow is a spring-driven, pre-filled pen platform for GLP-1 and peptide therapies, delivering doses up to 0.80 mL with a low-force mechanism and end-of-dos...

Ypsomed and BD (Becton, Dickinson and Company), a leading global medical technology company, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow glass prefillable syringe. This innovation is designed to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections.  

The YpsoMate autoinjector is an automated injection device for 1 mL long pre-filled glass or polymer syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients.The design can be customised for individual dosing requirements.

Ypsomed is expanding its clinical excellence offering to support faster and more reliable clinical trials for subcutaneous injectable drugs. With CliniPilot and the Clear-to-Clinic approach, Ypsomed combines ready-to-use devices with digital solutions to accelerate clinical evaluation of new therapies.

The UnoPen is an intuitive variable dose pen for insulin and other multidose therapies providing a familiar handling experience and high level of patient acceptance.

Ypsomed has received another industry award for its YpsoLoop autoinjector. At the Pharmapack Awards 2026, YpsoLoop won in the category “Patient-Centric Design,” recognizing its strong focus on supporting safe, intuitive self-injection, and innovating with purpose.

Reusable pens combining sustainability, versatiliy, and easy market access. From Ypsomed

The 2026 Pharmapack Awards, held January 21, 2026, celebrated and recognised leading companies in the pharmaceutical packaging sector paving the way for packaging and drug delivery excellence in the future. 

YpsoDose is the ready-to-use patch injector with minimum use steps to administer drug volumes up to 10 mL. With its intuitive use concept and ingenious technical solutions it ensures comfortable and safe injections for all conditions and environments while adapting to your formulation needs. It’s more than a device – it’s a reliable partner for patients, caregivers, and HCPs.

Pharmapack 2026 marks a significant milestone as it celebrates its 25th anniversary, bringing together global leaders in pharmaceutical packaging and drug delivery. In this exclusive interview, Ypsomed, a pioneering developer and manufacturer of subcutaneous self-injection solutions, shares insights into their innovative product lineup and their vision for the future of self-injection.

YpsoMate 5.5 large volume autoinjector is an automated injection device for 5.5 mL pre-filled glass syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients. Fully customisable.

Ypsomed is proud to announce that its YpsoLoop autoinjector has been named the winner in the “Drug Delivery and Device Innovation” category at the CPHI Pharma Awards 2025 in Frankfurt. The award recognizes groundbreaking achievements that advance patient care in drug delivery.

Combine SmartPilot with YpsoMate and begin capturing accurate, unbiased injection data while enabling intuitive, step-by-step user guidance. Transforming the proven YpsoMate autoinjector into a fully connected digital health solution facilitates your big data strategy.

Ypsomed continued on its growth trajectory in the first half of the 2025/26 financial year, the Delivery Systems business reached CHF 266.6 million of sales. This represents a 21.0% increase compared to the same period last year. The Delivery Systems EBIT surged to CHF 86.5 million, i.e. an EBIT margin of 32.4%. Including the divested Diabetes Care business and other one-off effects across all business areas, Ypsomed generated half-year sales of CHF 362.7 million and an EBIT of CHF 151.7 million. Following the divestment of the Diabetes Care business, we increase our focus on our core competence and market leading position in self-injection systems.

CliniPilot integrates with YpsoMate® 1.0 and 2.25 autoinjectors, transforming them into powerful digital tools forclinical trials. It fits seamlessly into existing trial workflows, allowing adherence tracking and replacing manualdiaries with real-time, objective and reliable data to remove human errors and documentation burden. No regulatoryapproval is required, allowing for immediate application in clinical trials, and its compatibility with standardEDC systems ensures easy integration into existing trial setups.

Ypsomed’s latest study, published in the peer-reviewed journal Medical Devices: Evidence and Research, puts this to the test. The human factors validation focused on the SmartPilot, a digital add-on that provides visual and auditory feedback during injection and automatically logs injection data for therapy monitoring. The goal: to determine whether patients, caregivers, and healthcare professionals could use SmartPilot successfully – even without prior training.

The YpsoMate® 2.25 and YpsoMate® 2.25 Pro configurationwith an 8 mm needle enhances the trusted YpsoMate®platform by providing greater versatility and improved patientcomfort. It retains the familiar YpsoMate® ergonomic designwith push-on-skin activation, reducing development andregulatory risks while ensuring reliable performance. By offeringreduced injection force and time, it accommodates a widerange of drug formulations for various therapy needs.

Ypsomed has achieved an important regulatory milestone in China: the packaging registration for the YpsoMate 1 mL has been officially approved. This approval authorizes Ypsomed to commence full-scale production of the YpsoMate 1 mL in strict accordance with the registered documentation, paving the way for commercial supply to customers.

Speed up time-to-market with customised platform products

As the pharmaceutical industry accelerates its drive towards net zero, the environmental impact of drug delivery devices is coming sharply into focus. Scope 3 emissions dominate company footprints, and end-of-life processing represents a significant proportion of a device’s CO2 emissions. This makes it essential to rethink device design and end-of-life processes. In this article, Thuysi Dao, Ypsomed's Sustainability Innovation Lead, outlines a two-pronged approach combining sustainable device design with real-world take-back and recycling initiatives, and explores how the company’s new YpsoLoop autoinjector platform embodies this vision.

YpsoMate 2.25 and YpsoMate 2.25 Pro autoinjectors are automated injection devices for 2.25 mL pre-filled glass or polymer syringes suitable for all patient groups. They can be configured with either an 8 mm or a ½” needle. The device is triggered by push-on-skin activation which is convenient, ergonomic, and preferred by patients. The YpsoMate 2.25 Pro is suitable for a large range of viscosities.

Burgdorf, 21.10.2025, 7 a.m. – Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2.25 ml platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while offering the convenience of a pre-filled, two-step autoinjector. YpsoLoop integrates into existing production environments, supporting a transition toward more sustainable drug delivery solutions.

Burgdorf – Ypsomed Holding AG (SIX: YPSN) announced today that it has successfully completed the sale of its Ypsomed Diabetes Care business to TecMed AG.

Burgdorf – The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for SmartPilot, a digital connectivity add-on developed by Ypsomed. The device transforms the YpsoMate autoinjector into a connected system that automatically captures and transmits injection data. The clearance marks an important step toward digital health solutions that offer deeper insights into therapy use, enable objective monitoring, and support improved adherence and treatment outcomes.

Burgdorf – Ypsomed (SIX: YPSN) is set to capture significant growth in multiple existing and emerging drug delivery markets and announces a mid-term ambition to reach total sales between CHF 0.9 and 1.1 billion and an EBIT between CHF 280 and 340 million in 2029/30 and to retain a ROCE around 20 % throughout the period.

Burgdorf, 10.10.2025, 7 a.m. – Ypsomed will establish its first manufacturing facility in the United States. The company has selected Holly Springs in Wake County, North Carolina, as the location and will invest around CHF 200 million in a first phase. This is another milestone in Ypsomed’s global growth strategy, bringing the company closer to its customers and enabling it to serve local markets directly. From end of 2027 onwards, the new site in Holly Springs will supply products for the U.S. market. 

Powering momentum, driving access

YpsoFlow is the new pre-filled spring-driven pen injector from Ypsomed. It provides patient-trusted usability with effortless precision. YpsoFlow is the GLP-1 and other peptide-based therapies pen platform of choice.

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target